Licensing Opportunities

There are four different areas ready for disruptive commercialization:

1. Population cancer screening

Screening for cancer markers in asymptomatic populations. Sample types include:

  • Liquid Biopsy (blood)
  • Thin Prep (for gynecological cancer)
  • Sputum
  • Urine
  • Stool

2. Treatment decisions for new or treated cancer patients

Cancer Tissue/Biopsy testing

  • Identification of mutations for targeted chemotherapy
  • Identification of splice variants for check point inhibitors

Liquid Biopsy

  • Monitoring for recurrence of malignancy following chemotherapy and other treatments

3. Companion diagnostics

  • Development of companion diagnostics for new targeted chemotherapies and check point inhibitors
  • Patient selection for clinical trials, using splice variant targeting

4. Clonal variation

Clonal variation is one of the factors that contributes towards resistance to chemotherapy, due to inter-cellular and intra-cellular variations. Adoption of appropriate treatment modalities based on identifying these clonal variants has the potential to improve treatment outcomes.

Dr Roger Hodkinson


MutantDx Inc.

17204 106A Avenue
Edmonton, Alberta
Canada T5S 1E6